NEOS Investment Management LLC Acquires 9,101 Shares of Elevance Health, Inc. $ELV

NEOS Investment Management LLC raised its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 45.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,971 shares of the company’s stock after buying an additional 9,101 shares during the period. NEOS Investment Management LLC’s holdings in Elevance Health were worth $9,361,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Elevance Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after buying an additional 141,747 shares in the last quarter. Sanders Capital LLC grew its holdings in Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after purchasing an additional 1,152,440 shares during the last quarter. Artisan Partners Limited Partnership increased its position in Elevance Health by 9.7% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company’s stock valued at $1,429,498,000 after buying an additional 324,399 shares in the last quarter. Norges Bank purchased a new position in shares of Elevance Health in the second quarter worth $1,148,379,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Elevance Health by 4.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,440,630 shares of the company’s stock valued at $788,616,000 after purchasing an additional 112,020 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Down 0.7%

Shares of Elevance Health stock opened at $344.40 on Wednesday. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The company has a market cap of $76.01 billion, a P/E ratio of 13.71, a PEG ratio of 1.93 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The firm has a fifty day moving average of $352.83 and a two-hundred day moving average of $333.24.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio is presently 27.39%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ELV shares. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Wells Fargo & Company dropped their target price on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Robert W. Baird lifted their price objective on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Truist Financial dropped their price target on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Finally, Mizuho set a $413.00 price objective on shares of Elevance Health in a report on Friday, January 9th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.